P. Tacken

发表

No Advantage of Cell-Penetrating Peptides over Receptor-Specific Antibodies in Targeting Antigen to Human Dendritic Cells for Cross-Presentation1

C. Figdor, G. Adema, A. Eek, 2008, The Journal of Immunology.

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

Carl G. Figdor, C. Figdor, R. Torensma, 2007, Nature Reviews Immunology.

The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.

C. Figdor, G. Adema, J. Tel, 2012, Blood.

The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells.

C. Figdor, R. Fokkink, P. Tacken, 2011, Biomaterials.

Targeting dendritic cells--why bother?

C. Figdor, P. Tacken, M. Kreutz, 2013, Blood.

Perspectives Targeting dendritic cells — why bother ?

C. Figdor, P. Tacken, M. Kreutz, 2013 .

Tracking targeted bimodal nanovaccines: immune responses and routing in cells, tissue, and whole organism.

C. Eich, C. Figdor, M. Srinivas, 2014, Molecular pharmaceutics.

Multimodal imaging of nanovaccine carriers targeted to human dendritic cells.

C. Figdor, H. Croes, M. Wijers, 2011, Molecular pharmaceutics.

Antibodies and carbohydrate ligands binding to DC‐SIGN differentially modulate receptor trafficking

C. Figdor, R. Torensma, P. Tacken, 2012, European journal of immunology.

Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines.

C. Figdor, P. Tacken, 2011, Seminars in immunology.

for Cross-Presentation Targeting Antigen to Human Dendritic Cells over Receptor-Specific Antibodies in No Advantage of Cell-Penetrating Peptides

C. Figdor, G. Adema, A. Eek, 2008 .

Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.

C. Figdor, C. Punt, G. Adema, 2005, Blood.

Relevance of DC‐SIGN in DC‐induced T cell proliferation

C. Figdor, R. Torensma, B. Joosten, 2007, Journal of leukocyte biology.

Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity.

C. Figdor, R. Fokkink, P. Tacken, 2011, Blood.

Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation.

C. Figdor, A. Cambi, T. Sparwasser, 2011, Blood.

Respiratory innate immune proteins differentially modulate the neutrophil respiratory burst response to influenza A virus.

U. Holmskov, K. Hartshorn, M. White, 2005, American Journal of Physiology - Lung cellular and Molecular Physiology.

Living up to a name: the role of the VLDL receptor in lipid metabolism

K. V. van Dijk, L. Havekes, M. Hofker, 2001, Current opinion in lipidology.

VLDL receptor deficiency enhances intimal thickening after vascular injury but does not affect atherosclerotic lesion area.

P. Quax, K. V. van Dijk, L. Havekes, 2002, Atherosclerosis.

LDL receptor deficiency unmasks altered VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice.

B. Teusink, K. V. van Dijk, D. Harats, 2000, Journal of lipid research.

Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.

C. Figdor, R. Torensma, P. Tacken, 2012, Biomaterials.

Targeting nanoparticles to dendritic cells for immunotherapy.

C. Figdor, F. Albericio, P. Tacken, 2012, Methods in enzymology.

Responses Cell Human Dendritic Cells for the Induction of T Glycoprotein Binding and Deliver Antigen to L-SIGN and DC-SIGN, Inhibit Viral Internalizing Antibodies to the C-Type Lectins,

C. Figdor, R. Torensma, T. Maruyama, 2012 .

THuman Dendritic Cells for the Induction of Glycoprotein Binding and Deliver Antigen to Lectins , L-SIGN and DC-SIGN , Inhibit Viral Internalizing Antibodies to the C-Type

C. Figdor, R. Torensma, T. Maruyama, 2005 .

Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.

C. Figdor, F. Albericio, R. Torensma, 2012, Nanomedicine.

strongly enhances adjuvanticity Targeted delivery of TLR ligands to human and mouse dendritic cells

C. Figdor, R. Fokkink, J. Lambeck, 2012 .

Monocyte CD64 or CD89 targeting by surfactant protein D/anti‐Fc receptor mediates bacterial uptake

J. J. Batenburg, P. Tacken, Paul J. Tacken, 2006, Immunology.

Effective Targeting of Pathogens to Neutrophils via Chimeric Surfactant Protein D/Anti-CD89 Protein1

K. Hartshorn, C. van Kooten, M. White, 2004, The Journal of Immunology.

D/Anti-CD89 Protein Neutrophils via Chimeric Surfactant Protein Effective Targeting of Pathogens to

K. Hartshorn, M. White, J. J. Batenburg, 2004 .

Internalizing Antibodies to the C-Type Lectins, L-SIGN and DC-SIGN, Inhibit Viral Glycoprotein Binding and Deliver Antigen to Human Dendritic Cells for the Induction of T Cell Responses

C. Figdor, R. Torensma, T. Maruyama, 2006, The Journal of Immunology.

Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicity.

C. Eich, C. Figdor, R. Torensma, 2017, Nanomedicine.

Targeting antigens to dendritic cells in vivo.

C. Figdor, R. Torensma, Ruurd Torensma, 2006, Immunobiology.

A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade

Miguel Ángel Martínez, A. Mondal, T. Logtenberg, 2021, Nature Communications.

A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade

Miguel Ángel Martínez, A. Mondal, T. Logtenberg, 2021, Nature communications.

Protection From Obesity in Mice Lacking the VLDL Receptor

K. V. van Dijk, L. Havekes, V. Dahlmans, 2001, Arteriosclerosis, thrombosis, and vascular biology.

Ex Vivo –Generated Dendritic Cells for ClinicalTrials versus In Vivo Targeting to Dendritic Cells: Critical Issues

C. Figdor, G. Adema, C. Pereira, 2007 .

Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro.

Fernando Albericio, M. C. Stuart, Ben Joosten, 2010, Journal of controlled release : official journal of the Controlled Release Society.

Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters

C. Punt, G. Adema, I. Joosten, 2012, Cancer Immunology, Immunotherapy.

Activation of Human Plasmacytoid Dendritic Cells by TLR9 Impairs FcγRII-Mediated Uptake of Immune Complexes and Presentation by MHC Class II

C. Figdor, C. Punt, D. Benítez-Ribas, 2008, The Journal of Immunology.

DEC‐205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells

C. Figdor, A. Cambi, G. Adema, 2011, European journal of immunology.

Human Plasmacytoid Dendritic Cells Phagocytose, Process, and Present Exogenous Particulate Antigen

C. Figdor, J. Tel, I. D. de Vries, 2010, The Journal of Immunology.

Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production.

C. Figdor, C. Punt, G. Adema, 2008, Blood.

ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation

C. Figdor, R. Torensma, P. Tacken, 2019, Molecules.

Effective generation of very low density lipoprotein receptor transgenic mice by overlapping genomic DNA fragments: high testis expression and disturbed spermatogenesis

T. Beumer, R. Frants, L. Havekes, 2004, Transgenic Research.

Class II Uptake of Immune Complexes and RII-Mediated γ Cells by TLR 9 Impairs Fc Activation of Human Plasmacytoid Dendritic

C. Figdor, C. Punt, D. Benítez-Ribas, 2008 .

Modulating effects of thyroid state on the induction of biotransformation enzymes by 2,3,7,8-tetrachlorodibenzo-p-dioxin.

T. Visser, A. Brouwer, A. Schuur, 1998, Environmental toxicology and pharmacology.

IFN-Targeting DCIR on human plasmacytoid dendritic cells results in antigen

C. Figdor, C. Punt, G. Adema, 2008 .

820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells

P. Loo, A. Mondal, T. Logtenberg, 2020, Journal for ImmunoTherapy of Cancer.

Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E.

L. Havekes, M. Hofker, P. Tacken, 2000, The Biochemical journal.